checkAd

PRA’s Center for Rare Diseases Launches Toolkit to Identify and Mitigate Risks to Rare Disease Clinical Programs - Seite 2

Nachrichtenquelle: globenewswire
22.03.2021, 21:01  |  101   |   |   

“PRA is so sincerely dedicated to putting the patient's experience first,” said Terry Jo Bichell, Founder & Director of COMBINEDBrain, RDAC Member. It is easy to give lip service and small concessions to patients, but PRA is actually digging deep into what it means for patients and their families to be a part of clinical trials. Even when a patient wants a new treatment, it is still stressful, scary, and time-consuming to take part in a trial. PRA is trying to understand that and make it better.”

While the Patient-Centric Trial Development Toolkit does focus on lessening the burden on patients to participate in clinical research, there are also several key benefits for sponsors such as avoiding significant costs related to inefficiency, high trial dropout rates, protocol amendments, and not being able to complete a trial on time.

To learn more about the importance of patient-centricity in clinical development or to download the toolkit, visit https://prahs.com/centers/center-for-rare-disease/trial-development-to ....

For more information about the Center for Rare Disease, please visit https://prahs.com/centers/center-for-rare-disease.

About PRA Health Sciences

PRA Health Sciences is one of the world’s leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 75 offices across North America, Europe, Asia, Latin America, Africa, Australia and the Middle East and approximately 19,000 employees worldwide. Since 2000, PRA has participated in approximately 4,000 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 95 drugs. To learn more about PRA, please visit www.prahs.com.

INVESTOR INQUIRIES: InvestorRelations@prahs.com 

MEDIA INQUIRIES: Laurie Hurst, Sr. Director, Communications and Public Relations
hurstlaurie@prahs.com | +1 (919) 786-8435


Seite 2 von 2
PRA Health Sciences Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de





0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

PRA’s Center for Rare Diseases Launches Toolkit to Identify and Mitigate Risks to Rare Disease Clinical Programs - Seite 2 Four-part, patient-focused toolkit is available for download at no cost and allows sponsors to identify risks to the efficiency and success of their trialsRALEIGH, N.C., March 22, 2021 (GLOBE NEWSWIRE) - PRA Health Sciences (NASDAQ: PRAH) …

Nachrichten des Autors

Titel
Titel
Titel
Titel